Cargando…
The density and spatial tissue distribution of CD8(+) and CD163(+) immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors
BACKGROUND: Clinical response to MAPK inhibitors in metastatic melanoma patients is heterogeneous for reasons still needing to be elucidated. As the patient immune activity contributes to treatment clinical benefit, the pre-existing level of immunity at tumor site may provide biomarkers of disease o...
Autores principales: | Massi, Daniela, Rulli, Eliana, Cossa, Mara, Valeri, Barbara, Rodolfo, Monica, Merelli, Barbara, De Logu, Francesco, Nassini, Romina, Del Vecchio, Michele, Di Guardo, Lorenza, De Penni, Roberta, Guida, Michele, Sileni, Vanna Chiarion, Di Giacomo, Anna Maria, Tucci, Marco, Occelli, Marcella, Portelli, Francesca, Vallacchi, Viviana, Consoli, Francesca, Quaglino, Pietro, Queirolo, Paola, Baroni, Gianna, Carnevale-Schianca, Fabrizio, Cattaneo, Laura, Minisini, Alessandro, Palmieri, Giuseppe, Rivoltini, Licia, Mandalà, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858711/ https://www.ncbi.nlm.nih.gov/pubmed/31730502 http://dx.doi.org/10.1186/s40425-019-0797-4 |
Ejemplares similares
-
Digital Quantification of Intratumoral CD8+ T-Cells Predicts Relapse and Unfavorable Outcome in Uveal Melanoma
por: Hurdogan, Ozge, et al.
Publicado: (2022) -
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients
por: De Logu, Francesco, et al.
Publicado: (2021) -
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
por: Del Vecchio, Michele, et al.
Publicado: (2023) -
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014) -
Characteristics of Real-World Patients with High-Risk BRAF(V600E/K)-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
por: Quaglino, Pietro, et al.
Publicado: (2023)